168
Participants
Start Date
September 30, 2011
Primary Completion Date
June 30, 2017
Study Completion Date
June 30, 2017
PEGASYS
The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
Hydroxyurea
Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
Aspirin
Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
Icahn School of Medicine at Mount Sinai, New York
Memorial Sloan-Kettering Cancer Center, New York
Weill Cornell Medical College, New York
Ospedale San Maartino Genova, Genova
Geisinger Cancer Center, Danville
Georgetown University Medical Center, Washington D.C.
San Matteo Hospital, Pavia
Wake Forest University Baptist Medical Center, Winston-Salem
Duke University Medical Center, Durham
Emory Hospital, Atlanta
John H. Stroger Hospital of Cook County, Chicago
University of Illinois at Chicago, Chicago
University of Kansas Cancer Center, Westwood
Hopitaux de Paris, Paris
University of Utah, Salt Lake City
Mayo Clinic, Scottsdale
USC Norris Comprehensive Cancer Center, Los Angeles
The Palo Alto Clinic, Palo Alto
Stanford University School of Medicine, Stanford
Ospedale Riuniti de Bergamo, Bergamo
University Of Florence, Florence
Universita Cattolica del Sacro Cuore, Rome
Belfast City Hospital, Belfast
Heart of England NHS Foundation Trust, Birmingham
Guy's and St. Thomas' NHS Foundation Trust, London
Myeloproliferative Disorders-Research Consortium
NETWORK
National Cancer Institute (NCI)
NIH
Roche Pharma AG
INDUSTRY
Ronald Hoffman
OTHER